Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of infection by SARS-CoV-2:~  1. symptoms of acute respiratory tract infection (sudden onset of at least one of the following: cough, fever, shortness of breath) and biomolecular diagnosis of SARS-CoV-2 infection; OR~ 2. any acute respiratory disease AND biomolecular diagnosis of SARS-CoV-2 infection; OR~ 3. severe acute respiratory infection (fever and at least one sign / symptom of respiratory disease eg cough, fever, shortness of breath) AND in need of hospitalization AND biomolecular diagnosis of SARS-CoV-2 infection;~* Eastern Cooperative Oncology Group Performance Status score 0 to 1;~* National Early Warning Score 0 to 4;~* Ability to understand and consent to participate in this clinical trial, manifested by signing the Informed Consent Form (ICF).~Exclusion Criteria:~* Inability to ingest / absorb the study drug orally through spontaneous ingestion or use of gastro / enteral tubes;~* Any finding of clinical observation (history / physical evaluation) that is interpreted by the investigating physician as a risk to participate in the trial;~* Any laboratory test findings that the investigating physician considers as a risk to the research participant as to his / her participation in the clinical study;~* Any ECG examination finding that the investigating physician considers as a risk to the research participant as to his / her participation in the trial;~* Known hypersensitivity to the components of the drugs used during the study;~* Women in pregnancy or breastfeeding;~* Body weight less than 15kg;~* Estimated glomerular filtration rate (CKD-Epidemiology Collaboration, CKD-EPI) \<30 mL / min;~* Aspartate aminotransaminase (AST) or alanine aminotransaminase (ALT)\> 5 times the upper limit of normality;~* Refusal to participate;~* Refusal to sign the informed consent form.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: ACTIVE_COMPARATOR): Standard of care (SOC) treatment
- SOC plus ivermectin 100 mcg/kg (Type: EXPERIMENTAL): SOC plus ivermectin 100 mcg/kg
- SOC plus ivermectin 200 mcg/kg (Type: EXPERIMENTAL): SOC plus ivermectin 200 mcg/kg
- SOC plus ivermectin 400 mcg/kg (Type: EXPERIMENTAL): SOC plus ivermectin 400 mcg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).